Somavert is a new treatment option for acromegaly
March 2006
Somavert is a new treatment option for acromegaly in Canada.
Acromegaly is caused by a benign pituitary tumour that results in oversecretion of growth hormone. If left untreated, it can cause serious complications such as disfigurement and blindness.
Somavert (pegvisomant) is for patients who don't respond to surgery, radiation, and/or other medical therapies for acromegaly.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote